Clinical research plays a vital role in the war on cancer. Through research we discover new and better ways to fight this disease, improve the quality of life for patients, and ultimately one day, to prevent cancer. Research studies, also called clinical trials or protocols, help develop better treatments to improve survival, understand how cancer grows and manage side effects of treatment to improve quality of life.
Pearlman offers clinical trials sponsored by the National Cancer Institute as well as pharmaceutical companies.
Clinical Trials: Protocols Available by Disease Site
A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients with 1-3 Positive Nodes, Hormone Receptor-Positive and HER-2 Negative Breast Cancer with Recurrence Score (RS) of 25 or Less.
A Randomized Placebo-Controlled Phase III Study of Duloxetine for Treatment of Aromatase Inhibitor-Associated Musculoskeletal Symptoms in Women with Early Stage Breast Cancer
Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-Risk, Hormone Receptor-Positive and HER2/neu Negative Breast Cancer
A Phase III Trial of 6 versus 12 Treatments of Adjuvant FOLFOX plus Celecoxib or Placebo for Patients with Resected Stage III Colon Cancer
EVEREST: EVErolimus for Renal Cancer Ensuing Surgical Therapy, A Phase III Study
Non-Small Cell Lung Cancer
Randomized Phase III Study of Maintenance Therapy with Bevacizumab, Pemetrexed, or a Combination of Bevacizumab and Pemetrexed Following Carboplatin, Paclitaxel and Bevacizumab for Advanced Non-Squamous NSCLC
A Randomized, Multicenter, Open-Label, Phase 2 Study of Paclitaxel-Carboplatin Chemotherapy Plus Necitumumab (IMC-11F8) Versus Paclitaxel-Carboplatin Chemotherapy Alone in the First-Line Treatment of Patients with Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC)
A Phase II Selection Design of Pharmacodynamic Separation of Carboplatin / Paclitaxel / Erlotinib or Erlotinib Alone in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients with Performance Status 2 (PS 2) Selected by Serum Proteomics
A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy Versus High-Dose Interferon α-2b for Resected High-Risk Melanoma
Randomized Phase II Clinical Trial of AZD6244 Hydrogen Sulfate (NSC-748727) and MK-2206 (NSC-749607) VS mFOLFOX in Patients with Metastatic Pancreatic Cancer after Prior Chemotherapy
The following disease sites have no studies available at this time: Gallbladder, Genitourinary, GIST, Head and Neck, Leukemia, Lymphoma, Myeloma, and Prostate.